BVBert B. Vargas

Bert B. Vargas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bert B. Vargas has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Variability of the modified Balance Error Scoring System at baseline using objective and subjective balance measures

    by Amaal J Starling, Danielle F Leong, Jamie M Bogle, Bert B Vargas

    Aim: To investigate preseason modified Balance Error Scoring System (mBESS) performance in a collegiate football cohort; to compare scores to an objective mobile balance measurement tool. Materials & methods: Eighty-two athletes completed simultaneous balance testing using mBESS and the King–Devick Balance Test, an objective balance measurement tool. Errors on mBESS and objective measurements in the double-leg, single-leg (SS) and tandem stances were compared. Results: Mean mBESS error score was 7.23 ± 4.65. The SS accounted for 74% of errors and 21% of athletes demonstrated the maximum error score. There was no significant correlation between mBESS score and objective balance score. Conclusion: The high variability and large number of errors in the SS raises concerns over the utility of the SS in identifying suspected concussion.


  • A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine

    by Amaal J. Starling, Bert B. Vargas

    Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary.


  • Teleconcussion: An Innovative Approach to Screening, Diagnosis, and Management of Mild Traumatic Brain Injury

    by Bert B. Vargas, Dwight D. Channer, David W. Dodick, Bart M. Demaerschalk

    Concussion awareness and management in sports have gained a great deal of attention in light of research illustrating the potentially devastating consequences of repeated traumatic brain injuries. In order to address this public health crisis, numerous states have passed legislation that mandates medical clearance before being eligible to return to play of concussed athletes by a qualified healthcare provider. As the number of qualified healthcare providers with expertise in the diagnosis and management of concussions remains very small, patient safety and the ability to fulfill these legislative return-to-play requirements present unique problems to rural communities without easy access to subspecialty care. Telemedicine is a possible means by which to address the needs of the rural student-athlete.


  • Posttraumatic headache

    by Bert B. Vargas, David W. Dodick

    Posttraumatic headache (PTH) is a commonly occurring and potentially disabling consequence of concussion and mild traumatic brain injury (mTBI). This brief review highlights recent advances in the epidemiology, evaluation, and management of concussion, mTBI, and PTH. Current epidemiological studies suggest that previous estimates of concussion and mTBI incidence are grossly underestimated and have also helped to identify specific activities and demographic groups that might be more susceptible. Concussion results in profound metabolic derangements during which the brain is potentially vulnerable to repeat injury and permanent damage. Imaging studies such as magnetic resonance (MR) spectroscopy and diffusion tensor imaging have proven to be effective at identifying these abnormalities both acutely and also weeks after symptoms resolution. To date, there have been no randomized, placebo-controlled studies supporting the efficacy of any treatment for PTH and current therapeutic decisions are guided only by expert opinion and current evidence-based guidelines for the treatment of specific primary headache phenotypes, the most commonly occurring of which is migraine. Despite numerous advances in the awareness, pathophysiology, and diagnostic workup of concussion, mTBI, and PTH, there is a paucity of evidence-based guidance regarding treatment.


    • 20 September 2011
      • Vol. 14  (5) , 435-40

    Occipital nerve stimulation with the Bion® microstimulator for the treatment of medically refractory chronic cluster headache.

    by Natalie H Strand, Terrence L Trentman, Bert B Vargas, David W Dodick

    Chronic cluster headache is a severely disabling neurological disorder. Evidence from open-label case series suggest that occipital nerve stimulation may be effective for the treatment of chronic cluster headache. To evaluate the effectiveness of a microstimulator for chronic cluster headache. Prospective, observational feasibility study plus medical record review. Academic medical center. Four patients with medically refractory chronic cluster headache underwent implantation of a unilateral bion microstimulator. In-person follow-up was conducted for 12 months after implantation, and a prospective follow-up chart review was carried out to assess long term outcome. Three of the participants returned their headache diaries for evaluation. The mean duration of chronic cluster headache was 14.3 years (range 3 to 29 years). Pain was predominantly or exclusively retroocular/periocular. One participant demonstrated a positive response (> 50% reduction in cluster headache frequency) at 3 months post-implant, while there were 2 responders at 6 months. At least one of the participants continued to show > 60% reduction in headache frequency at 12 months. A chart review showed that at 58-67 months post-implant, all 3 participants reported continued use and benefit from stimulation. No side-shift in attacks was noted in any participant. Adverse events were limited to 2 participants with neck pain and/or cramping with stimulation at high amplitudes; one required revision for a faulty battery. Small patient population without control group. Not blinded or randomized. Unilateral occipital nerve stimulation, using a minimally invasive microstimulator, may be effective for the treatment of medically refractory chronic cluster headache. This benefit may occur immediately after implantation, remain sustained up to 5 years after implantation, and occur despite the anterior location of the pain. Prospective, randomized controlled trials of occipital nerve stimulation in chronic cluster headache should proceed.


  • Posttraumatic headache in combat soldiers and civilians: What factors influence the expression of tension-type versus migraine headache?

    by Bert B. Vargas

    Traumatic brain injury (TBI) is highly prevalent in the United States and a common cause of posttraumatic headache (PTH) and disability. The criteria that define PTH include timelines and features that are not based on clearly established physiologic data and may result in the underrecognition and incorrect treatment of these headaches. A clear understanding of the classification of PTH becomes even more elusive when one takes into account combat-related head injuries, which are also highly prevalent and frequently lead to headaches with features that are different from those suffered by civilians with PTH. The fact that tensiontype headache phenotypes are uncommon in military personnel with PTH suggests that there are features unique to the combat environment, which may predispose to the development of migraine. Further insight may also be obtained from soldiers with PTH with regard to the true pathophysiology and timelines of headache in the context of TBI.


    • 23 May 2009
      • Vol. 12  (3) , 621-8

    Greater occipital nerve stimulation via the Bion microstimulator: implantation technique and stimulation parameters. Clinical trial: NCT00205894.

    by Terrence L Trentman, David M Rosenfeld, Bert B Vargas, Todd J Schwedt, Richard S Zimmerman, David W Dodick

    Millions of patients suffer from medically refractory and disabling primary headache disorders. This problem has led to a search for new and innovative treatment modalities, including neuromodulation of the occipital nerves. The primary aim of this study is to describe an implantation technique for the Bion microstimulator and document stimulation parameters and stimulation maps after Bion placement adjacent to the greater occipital nerve. The secondary aim is to document outcome measures one year post-implant. Prospective, observational feasibility study. Nine patients with medically refractory primary headache disorders participated in this study. Approximately 6 months after Bion insertion, stimulation parameters and maps were documented for all patients. At one year, outcome measures were collected including the Migraine Disability Assessment Score. At 6 months, the mean perception threshold was 0.47 mA, while the mean discomfort threshold was 6.8 mA (stimulation range 0.47-6.8 mA). The mean paresthesia threshold was 1.64 mA and the mean usage range was 16.0. There were no major complications reported such as device migration, infection, or erosion. One patient stopped using her Bion before the 12-month follow-up visit. At one year, 7 of the 8 patients were judged as having obtained fair or better results in terms of reduction of disability; 5 patients had greater than a 90% reduction in disability. Small, heterogeneous patient population without control group. Not blinded or randomized. The Bion can be successfully inserted adjacent to the greater occipital nerve in an effort to treat refractory primary headache disorders. This microstimulator may provide effective occipital stimulation and headache control while minimizing the risks associated with percutaneous or paddle leads implanted subcutaneously in the occipital region.


  • 2007 Scottsdale Headache Symposium

    by Bert B Vargas, David W Dodick

    Since 1976, the American Headache Society has organized annual educational symposia which are now routinely held in Scottsdale, Arizona. Taught by a faculty consisting of many of the world's leading experts in headache, the objectives of this symposium are to review the clinical spectrum of headache and facial pain as well as recent advances in the acute treatment and long-term management of these disorders.